Harris HA

No ORCID on file · 6 papers in corpus
other 2008
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2008.08.008

Selective estrogen receptor modulators (SERMs) have the potential to treat estrogen sensitive diseases such as uterine leiomyoma and endometriosis, which are prevalent in reproductive age women. However, SERMs also increase the risk of deve…

review 2007
Molecular Endocrinology ·doi:10.1210/me.2005-0459

The unexpected discovery of a second form of the estrogen receptor (ER), designated ERbeta, surprised and energized the field of estrogen research. In the 9 yr since its identification, the remarkable efforts from academic and industrial sc…

other 2006
European journal of pharmacology ·doi:10.1016/j.ejphar.2006.09.033

ERB-041 (2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3 benzoxazol-5-ol) is a selective estrogen receptor-beta agonist with activity in rodent models of rheumatoid arthritis and endometriosis. Clinical trials for these diseases are underway: howe…

review 2006
Ernst Schering Foundation symposium proceedings ·doi:10.1007/2789_2006_021

It has now been over 10 years since Jan-Ake Gustafsson revealed the existence of a second form of the estrogen receptor (ERbeta) at a 1996 Keystone Symposium. Since then, substantial success has been made in distinguishing its potential bio…

2006
Nuclear receptor signaling ·doi:10.1621/nrs.04012

In the nine years since the unexpected discovery of a second form of the estrogen receptor (ER), ERbeta has been mentioned in about 2,800 literature citations. Such prolific research is testimony to interest in explaining its role in estrog…

article 2004
Human Reproduction ·doi:10.1093/humrep/deh711

BACKGROUND: Endometriosis is a common gynaecological problem of uncertain aetiology. It affects primarily young, reproductive-aged women and can result in chronic pelvic pain and infertility. Current approved therapies have significant side…